Neuroma Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma
Verified date | August 2005 |
Source | AlgoRx Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.
Status | Completed |
Enrollment | 60 |
Est. completion date | February 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Males or females aged >18 years - Foot X-ray to rule out alternative pathology, and ultrasound or magnetic resonance imaging (MRI) to confirm the presence of a neuroma within 6 months of study entry - Evidence of either a primary or post surgical recurrence neuroma - A score of 4 or greater on the Average Foot Pain Severity Numeric Rating Scale (NRS) during the week prior to randomization - Failed conservative treatment such as wide shoes, orthotics, arch supports, or oral and/or injected analgesics - Signed an Informed Consent form approved by the Institutional Review Board - For female subjects: is surgically sterile, at least 2 years postmenopausal, or using a medically acceptable method (as determined by the Principal Investigator) of birth control; if of child-bearing potential is not pregnant (have a documented negative urine pregnancy test prior to enrollment), is not planning to get pregnant (during the time course of the study), or is not lactating - Able to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments Exclusion Criteria: - History of clearly documented allergic reaction to lidocaine or capsaicin. - Prior participation in ALGRX 4975 study. - Presence of any medical condition or instability that, in the judgment of the Investigator, might adversely impact the conduct of the study and the collection of data, including chronic conditions that are likely to alter the rate of healing or are likely to result in safety complications unrelated to the study medication, such as diabetes mellitus or extensive vascular disease - Treatment of neuroma with a narcotic analgesic - Other painful foot pathology - Active cutaneous, or other disease, at the anticipated site of study drug injection - Laboratory results that are both out of normal range and, in the opinion of the Investigator, clinically significant - Drug or alcohol abuse within the past 2 years - Require regular oral steroid medication, except for stable use (6 months or longer on the same scheduled dose) for mild or moderate asthma - Use of an investigational medication in the 30 days prior to the current study or scheduled to receive such an agent while participating in the current study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Crossroads Research, Inc. | Owings Mills | Maryland |
United States | Jean Brown Research | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
AlgoRx Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weekly average foot pain severity scores | |||
Secondary | The sum of weekly average foot pain severity scores | |||
Secondary | Interference item scores of the Brief Pain Inventory | |||
Secondary | Weekly number of analgesic units taken |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Recruiting |
NCT05008185 -
Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation
|
||
Completed |
NCT02205385 -
Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation
|
N/A | |
Completed |
NCT02316262 -
Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation
|
N/A | |
Completed |
NCT04931056 -
A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.
|
||
Completed |
NCT01632709 -
Pathophysiology of Post Amputation Pain
|
Phase 4 | |
Completed |
NCT02528266 -
Surgical Treatment of Symptomatic Neuroma "Stop Neuroma"
|
N/A | |
Withdrawn |
NCT01374191 -
Botulinum Toxin Type A for Neuroma Pain
|
Phase 2 | |
Enrolling by invitation |
NCT06164392 -
Evaluation of Neuroma Perfusion With Indocyanine Green Fluorescence Angiography
|
Phase 4 | |
Completed |
NCT03484429 -
Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
|
N/A | |
Completed |
NCT03051113 -
Identification of Neuromas by High Resolution Ultrasound in Patients With Peripheral Nerve Injury and Amputations
|
||
Completed |
NCT02993276 -
Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma
|